Current Controlled Trials in Cardiovascular Medicine, 2004 Background Although percutaneous coronary intervention (PCI) is becoming the standard therapy in ST-segment elevation myocardial infarction (STEMI), to date most patients, even in developed countries, are reperfused with intravenous thrombolysis or do ...
Visser Cees A +5 more
doaj +1 more source
Journal of Peptide Science, Volume 30, Issue 7, July 2024.The development of highly affine, selective peptides and small molecules in recent years has allowed peptide drugs (PDCs) and small molecule–drug conjugates (SMDCs) to increasingly compete with antibody–drug conjugates (ADCs). This review summarises and describes integrin‐addressing PDCs and SMDCs, while highlighting points of great interest.
Jannik Paulus, Norbert Sewald
wiley +1 more source
Prophylaxis of Experimental Endocarditis With Antiplatelet and Antithrombin Agents: A Role for Long-term Prevention of Infective Endocarditis in Humans? [PDF]
, 2017 Background. Infective endocarditis (IE) mostly occurs after spontaneous low-grade bacteremia. Thus, IE cannot be prevented by circumstantial antibiotic prophylaxis.
Chaouch, Aziz +7 more
core
Folia Histochemica et Cytobiologica, 2010 Abciximab (Abci) and eptifibatide (Epti) are antiaggregate drugs which may reduce thrombotic complications inacute coronary syndromes. The aim of this work was the investigation of the interaction between the phospholipid-GPIIb/IIIa glycoprotein complex ...
Ewa Gorodkiewicz +2 more
doaj
Granulocyte-colony-stimulating factor mobilizes bone marrow stem cells in patients with subacute ischemic stroke: the Stem Cell Trial of Recovery EnhanceMent After Stroke (STEMS) Pilot Randomized, Controlled Trial (ISRCTN 16784092) [PDF]
, 2006 Background and Purpose - Loss of motor function is common after stroke and leads to significant chronic disability. Stem cells are capable of self-renewal and of differentiating into multiple cell types, including neurones, glia, and vascular cells.
Bath, Philip M.W. +7 more
core +1 more source
Farmeconomia: Health Economics and Therapeutic Pathways, 2005 Inhibition of platelet glycoprotein IIb/IIIa (GP IIb/IIIa) receptor prevents platelet aggregation by controlling its final common pathway, the cross-binding of fibrinogen, bridging across adjacent platelets.
Lorenzo Pradelli
doaj +1 more source
Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome [PDF]
, 2017 Aims To investigate the efficacy and outcome of emergency percutaneous coronary interventions (PCI) in patients with stent thrombosis. Methods and results Between 1995 and 2003, 6058 patients underwent bare-metal stent implantation, of which 95 (1.6 ...
Eberli, Franz R. +10 more
core
FbsA, a fibrinogen-binding protein from Streptococcus agalactiae, mediates platelet aggregation [PDF]
, 2005 The bacterium Streptococcus agalactiae is an etiologic agent in the pathogenesis of endocarditis in humans. FbsA, a fibrinogen-binding protein produced by this pathogen, is considered an important virulence factor.
Fitzgerald, J Ross +7 more
core +1 more source
Thromboembolic Complications During Endovascular Treatment of Ruptured Intracranial Aneurysms - Prevention and Therapy [PDF]
, 2012 As complicações tromboembólicas são as mais frequentemente reportadas durante a terapêutica endovascular de aneurismas intracranianos com espiras metálicas.
Baptista, T +4 more
core
Кардиоваскулярная терапия и профилактика, 2008 The review presents literature data on the key role of platelet aggregation (PA) for intracoronary thrombogenesis in various acute coronary syndromes (ACS) and percutaneous coronary interventions (PCI).
T. A. Batyraliev +4 more
doaj